A case of fulminant demyelinating disease associated with golimumab treatment

Clin Neurol Neurosurg. 2020 Aug:195:105887. doi: 10.1016/j.clineuro.2020.105887. Epub 2020 May 16.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Demyelinating Autoimmune Diseases, CNS / chemically induced*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Male
  • Spondylitis, Ankylosing / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • golimumab